您好,欢迎来到化工原料网! [登录] [免费注册]
化工原料网
位置:首页 > 产品库 > LXH254
立即咨询
咨询类型:
     
*姓名:
*电话:
*单位:
Email:
*留言内容:
请详细说明您的需求。
*验证码:
 
LXH254
本产品不向个人销售,仅用作科学研究,不用于任何人体实验及非科研性质的动物实验。
LXH254图片
包装与价格:
包装价格(元)
5mg电议
10mg电议
25mg电议
50mg电议

产品介绍
LXH254 是一种有效的、选择性的、具有口服活性的 II 型 BRAF 和 CRAF 抑制剂,对 CRAF 和 BRAF 的 IC50 值分别为 0.072 和 0.21 nM。

Animal experiment:

Mice[1]SCID beige female tumor-bearing NCI-H358 mice, n=8 per group, are randomized into 3 groups 14 days post tumor cell inoculation with an average tumor volume range of 259.44- 262.47mm3. Animals are administered an oral dose of either vehicle, LXH254 at 30mg/kg or 200mg/kg daily for 14 consecutive days at a dosing volume of 10 mL/kg of animal body weight during course of treatment. Tumor volumes are measured by digital caliper 3 times a week and body weights of all animals are recorded through the course of treatment.Female nude tumor bearing Calu6 mice, n=6 per group are randomized into treatment groups on day 17 following tumor implantation, when the average tumor volume is 180 mm3. Treatments with LXH254 are initiated on Day 17 and continued for 16 days. Dosing volume is 10 mL/kg. Tumor volumes are collected at the time of randomization and twice weekly thereafter for the study duration.Nude female mice tumor bearing NCI-H358, n=8 per group, are randomized into 2 groups with an average tumor volume range of 275.74 mm3. Animals are administered an oral dose of either vehicle or LXH254 at 100 mg/kg daily for 14 consecutive days at a dosing volume of 10 mL/kg of animal body weight during course of treatment. Tumor volumes are measured by digital caliper 3 times a week and body weights of all animals are recorded through the course of treatment[1].

产品描述

LXH254 is a potent CRAF inhibitor extracted from patent WO2018051306A1, Compound A. LXH254 also is a potent BRAF inhibitor.

LXH254 (Compound A) is an adenosine triphosphate (ATP)-competitive inhibitor of BRAF (also referred to herein as b-RAF or b-Raf) and CRAF (also referred to herein as c-RAF or c- Raf) protein kinases. Throughout the present disclosure, LXH254 is also referred to as a c-RAF (or CRAF) inhibitor or a C-RAF/c-Raf kinase inhibitor. In cell-based assays, LXH254 has demonstrated anti-proliferative activity in cell lines that contain a variety of mutations that activate MAPK signaling. Moreover, LXH254 is a Type 2 ATP -competitive inhibitor of both B-Raf and C-Raf that keeps the kinase pocket in an inactive conformation, thereby reducing the paradoxical activation seen with many B-Raf inhibitors, and blocking mutant RAS-driven signaling and cell proliferation[1].

Treatment with LXH254 (Compound A) generates tumor regression in several KRAS-mutant models including the NSCLC-derived Calu-6 (KRAS Q61K) and NCI-H358 (KRAS G12C). LXH254 exhibits efficacy in numerous MAPK-driven human cancer cell lines and in xenograft tumors representing model tumors harboring human lesions in KRAS, NRAS and BRAF oncogenes[1].

References:
[1]. CAPONIGRO, Giordano, et al. THERAPEUTIC COMBINATIONS COMPRISING A RAF INHIBITOR AND A ERK INHIBITOR. WO 2018051306 A1 20180322